A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes

Phase 1 Completed 38 enrolled Novo Nordisk A/S HNEC TEST · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This trial was conducted in Europe. The aim of this study was to investigate the total exposure of NN5401 (insulin degludec/insulin aspart) in children, adolescents and adult subjects with type 1 diabetes.

Timeline

Start: 2010-06
Primary completion: 2010-11
Completion: 2010-11

Publications

Results Biester T, Danne T, Blasig S, Remus K, Aschemeier B, Kordonouri O, Bardtrum L, Haahr H. Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes. Pediatr Diabetes. 2016 Dec;17(8):642-649. doi: 10.1111/pedi.12358. Epub 2016 Jan 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	insulin degludec/insulin aspart	Protein / enzyme biologic	0.5 iu/kg	Subcutaneous

A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes

Summary

Timeline

Publications

Drugs

Indications